Trial · NCT03870529
High Dose Vitamin A Compound in Treating Participants With Resectable Non-Small Cell Lung Cancer
NCT03870529, Early phase 1, Terminated, Wake Forest University Health Sciences; results first posted 2024-01-09
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. High Dose Vitamin A Compound in Treating Participants With Resectable Non-Small Cell Lung Cancer. Trials, record NCT03870529. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03870529
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- High Dose Vitamin A Compound in Treating Participants With Resectable Non-Small Cell Lung Cancer
- NCT number
- NCT03870529
- Status
- Terminated
- Phases
- Early phase 1
- Enrollment
- 20 participants, actual
- Lead sponsor
- Wake Forest University Health Sciences
- Conditions
- Non Small Cell Lung Cancer, Stage I Lung Cancer, Stage Ib Lung Carcinoma, Stage IA Lung Carcinoma AJCC V7, Stage IIA Lung Carcinoma, Stage IIIA Lung Carcinoma
- Interventions
- Vitamin A Compound, Therapeutic Conventional Surgery
- First posted
- 2019-03-12
- Last updated
- 2024-01-09
- Results first posted
- 2024-01-09
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Presence or Absence of Germinal Centers in Resected Tissue | Up to 2 years | Presence/absence of germinal centers (GCs) in resected cancer tissues from patients who receive neoadjuvant vitamin A and controls. |
| Secondary | Proportion of Germinal Centers in Lymph Nodes | Up to 2 years | Measurement of GCs per unit area in adjacent lymph nodes will be assessed using semi-quantitative designation (Score of high, moderate, low, or absent) in patients who receive neoadjuvant vitamin A and controls. |
| Secondary | Presence or Absence of Tumor Necrosis | Up to 2 years | Pathologic response will be defined by tumor necrosis which will be dichotomized as present or absent in patients who receive neoadjuvant vitamin A and controls |
| Secondary | Overall Survival | Up to 2 years | Overall survival of patients receiving neoadjuvant Vitamin A and in controls. |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Presence or Absence of Germinal Centers in Resected Tissue | Up to 2 years | No samples were analyzed for outcomes and the study was stopped therefore data was not collected for outcome measures | ||
| SECONDARY | Proportion of Germinal Centers in Lymph Nodes | Up to 2 years | No samples were analyzed for outcomes and the study was stopped therefore data was not collected for outcome measures | ||
| SECONDARY | Presence or Absence of Tumor Necrosis | Up to 2 years | No samples were analyzed for outcomes and the study was stopped therefore data was not collected for outcome measures | ||
| SECONDARY | Overall Survival | Up to 2 years | No samples were analyzed for outcomes and the study was stopped therefore data was not collected for outcome measures |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Vitamin A Compound | 11 | |
| Overall Study | STARTED | Therapeutic Conventional Surgery | 9 | |
| Overall Study | COMPLETED | Vitamin A Compound | 11 | |
| Overall Study | COMPLETED | Therapeutic Conventional Surgery | 9 | |
| Overall Study | NOT COMPLETED | Vitamin A Compound | 0 | |
| Overall Study | NOT COMPLETED | Therapeutic Conventional Surgery | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Vitamin A Compound | 0 | 11 |
| Total, all-cause mortality | Therapeutic Conventional Surgery | 0 | 9 |
| Total, other adverse events | Vitamin A Compound | 0 | 11 |
| Total, other adverse events | Therapeutic Conventional Surgery | 0 | 9 |
| Total, serious adverse events | Vitamin A Compound | 0 | 11 |
| Total, serious adverse events | Therapeutic Conventional Surgery | 0 | 9 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P30CA012197 | Cancer Center Support Grant | MESA, RUBEN A. | WAKE FOREST UNIVERSITY HEALTH SCIENCES | NATIONAL CANCER INSTITUTE | 1985 to 2025 |
Source NIH RePORTER
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Vitamin A Compound vs Therapeutic Conventional Surgery: deaths from any cause | Trial comparisons |
| Vitamin A Compound vs Therapeutic Conventional Surgery: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03870529
GET https://conductscience.org/api/trials/v1/NCT03870529/registered